Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up (2006)
Gossec, L., Le Henanff, A., Breban, M., Vignon, E., Claudepierre, P., Devauchelle, V., ...
Objective. To evaluate the continuation and safety of treatment with infliximab in ankylosing spondylitis (AS) over a 2-yr period. Methods. This study was an open, observational, 2-yr extension study...
Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up (2006)
Gossec, L., Henanff, A. Le, Breban, M., Vignon, E., Claudepierre, P., Devauchelle, V., ...
Objective. To evaluate the continuation and safety of treatment with infliximab in ankylosing spondylitis (AS) over a 2-yr period. Methods. This study was an open, observational, 2-yr extension study...
Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up (2006)
Gossec, L., Henanff, A. Le, Breban, M., Vignon, E., Claudepierre, P., Devauchelle, V., ...
Objective. To evaluate the continuation and safety of treatment with infliximab in ankylosing spondylitis (AS) over a 2-yr period. Methods. This study was an open, observational, 2-yr extension study...
Breban, M., Vignon, E., Claudepierre, P., Devauchelle, V., Wendling, D., Lespessailles, E., ...
Objective. To evaluate the efficacy and safety of a loading regimen of the anti‐tumour necrosis factor α (TNF‐α) antibody infliximab in predominantly axial severe ankylosing...
Reviron, D, Perdriger, A, Toussirot, E, Wendling, D, Balandraud, N, Guis, S, ...
No abstract available.
Positive association of the HLA DMB1*0101-0101 genotype with rheumatoid arthritis (1999)
Perdriger, A, Guggenbuhl, P, Chales, G, Yaouanq, J, Quelvennec, E, Bonnard, MN, ...
Infliximab in the treatment of rheumatoid arthritis
Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis (RA). This chimeric antibody binds with high affinity to both soluble...